Clinical trials: Stage II Breast Carcinoma
Breast Cancer
SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00896623
- Testing
- mutation analysis, polymorphism analysis, surface-enhanced laser desorption/ionization-time of flight mass spectrometry
- Volunteers
- 1,577 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005635
- Testing
- trastuzumab, paclitaxel
- Where
- United States
- Sponsor
- Genentech, Inc.
Breast Cancer
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00408408
- Testing
- bevacizumab, capecitabine, cyclophosphamide
- Where
- 442 sites in United States, Canada and 1 more
- Volunteers
- 1,206 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer
This study will determine if docetaxel will be administered before or after doxorubicin/cyclophosphamides in an adjuvant chemotherapy regimen to be evaluated in a subsequent phase III trial.
- Trial name
- NCT00201708
- Testing
- Docetaxel, Doxorubicin, Cyclophosphamide (AC)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Prognostic Value of Stem Cell Related Markers
The goal of the investigators study is to identify a prognostic marker that will evaluate the probability of recurrence in patients with stage 0-II breast cancer following surgery to remove the tumor.
- Trial name
- NCT01265225
- Where
- Israel
- Sponsor
- The Baruch Padeh Medical Center, Poriya
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
The goal of this randomized clinical trial is to learn if a healthy eating pattern called the MIND eating plan can reduce cancer-related cognitive impairment (commonly called "chemobrain") and other symptoms commonly experienced…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Trial name
- MIND-TNBC (NCT06582615)
- Testing
- Biospecimen Collection, Cognitive Assessment, Dietary Intervention
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Breast Cancer, Lung Cancer
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
The purpose of this study is to determine the response rate by RECIST criteria of oral dichloroacetate in patients with recurrent and/or metastatic and pretreated breast and non-small cell lung cancer.
- Trial name
- NCT01029925
- Testing
- Dichloroacetate (DCA)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
The investigators propose to conduct a Phase I/randomized Phase II study design in order to test the tolerability and efficacy of AZD0530 (also called saracatinib) when used together with anastrozole in therapy for ER+ and/or…
- Trial name
- NCT01216176
- Testing
- Anastrozole, AZD0530 (saracatinib)
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Joyce Marie Slingerland, MD
Breast Cancer
Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer
The purpose of the study is to assess the benefit of panobinostat monotherapy given either orally or i.v. to women with HER2-positive locally recurrent or metastatic breast cancer
- Trial name
- NCT00777335
- Testing
- Panobinostat - LBH589
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Translational Research in Oncology
Premenopausal HR+/HER2- Metastatic Breast Cancer
PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study
This study is a prospective, two-arm, randomized phase II study of talazoparib versus talazoparib plus atezolizumab in ER+ premeonopausal women with metastatic breast cancer harboring HRD scar 1st line treatment: GnRH agonist +…
- Trial name
- Young-PALETTA (NCT04819243)
- Testing
- Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab, Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib,
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Samsung Medical Center
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer, Fatigue
Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer
RATIONALE: Infliximab may help improve energy levels in patients who have undergone treatment for breast cancer. PURPOSE: This phase II trial is studying how well infliximab works in treating cancer-related fatigue in…
- Trial name
- NCT00112749
- Testing
- infliximab, Clinical Assessment, Self-report questionnaires
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Jonsson Comprehensive Cancer Center
HER-2 Positive Breast Cancer
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
This study will evaluate the safety and efficacy of eribulin in combination with carboplatin and trastuzumab in the neoadjuvant setting in subjects who are human epidermal growth factor receptor (HER)2 positive and are clinically…
- Trial name
- NCT01388647
- Testing
- eribulin, carboplatin, trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Vector Oncology
HER2-positive Breast Cancer, Recurrent Breast Cancer
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
This phase II trial studies how well capecitabine, cyclophosphamide, lapatinib ditosylate, and trastuzumab work in treating patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01873833
- Testing
- capecitabine, cyclophosphamide, lapatinib ditosylate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Women With Primary Breast Cancer
A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.
TITLE: A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Breast Cancer.
- Trial name
- NCT02225652
- Testing
- FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel
- Where
- Italy
- Volunteers
- 11 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Breast Cancer
Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
The study includes Phase I dose escalation and expansion and Phase II combination therapy. It uses a multicenter, open-label, non-randomized design to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy…
- Trial name
- NCT07697443
- Testing
- TQB3126
- Where
- 6 sites in China
- Volunteers
- 300 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Neoplasms
PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer
The purpose of this study is to test the safety of PTK787/ZK222584 and Letrozole when given in combination, and to see what effects they have on breast cancer that has metastasized.
- Trial name
- NCT00263198
- Testing
- PTK787/ZK222584, Letrozole
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
This research study is looking at tissue samples from women with breast cancer who were treated on clinical trial NCCTG-N9831. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more…
- Trial name
- NCT00898898
- Testing
- diagnostic laboratory biomarker analysis
- Volunteers
- 2,837 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Breast Cancer
Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies
Recent clinical studies have shown that the combination of lapatinib and trastuzumab has superior antitumor activity compared to either single drug in both neoadjuvant and metastatic setting and is well tolerated.
- Trial name
- NCT02238509
- Testing
- Lapatinib, Trastuzumab
- Where
- 36 sites in Italy
- Volunteers
- 154 people
- Sponsor
- Consorzio Oncotech
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00295893
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.